Skip to main content
. 2022 Sep 26;2022(9):CD015048. doi: 10.1002/14651858.CD015048.pub2

Winter 2007.

Study characteristics
Methods The current study was a retrospective review of data from women treated with platinum and paclitaxel combination chemotherapy on one of 6 prospective randomised clinical trials conducted by GOG: protocols 111, 114, 132, 152, 158 and 172
GOG 111: included LVRD (> 1 cm) stage III/IV EOC (eligible women = 123)
GOG 114: included SVRD (< 1 cm) stage III EOC (eligible women = 226)
GOG 132: included LVRD (> 1 cm) stage III/IV EOC (eligible women = 147)
GOG 152: included LVRD (> 1 cm) stage III EOC (eligible women = 397)
GOG 158: included LVRD (> 1 cm) stage III EOC (eligible women = 792)
GOG 172: included SVRD (≤ 1 cm) stage III EOC (eligible women = 210)
Participants Data from 1895 women with stage III invasive EOC who underwent primary surgical cytoreduction followed by paclitaxel/platinum chemotherapy, while participating in one of six GOG clinical trials, was analysed for the present study
The median age was 57 years (range: 16 to 86 years)
All 1895 women had FIGO stage III
Histological cell type was as follows: serous: 1392 (73.5%), endometrioid: 166 (8.8%), mucinous: 34 (1.8%), mixed epithelial: 142 (7.5%), adenocarcinoma unspecified: 49 (2.6%), clear cell: 62 (3.3%), undifferentiated: 26 (1.4%), other: 24 (1.3%)
179 (9.5%) women had tumour grade 1, 719 (37.9%) had grade 2 and 997 (52.6%) women had tumour grade 3
Tumour grade details: 1: 179 (9.5%), 2: 719 (37.9%), 3: 997 (52.6%)
Ethnicity details: White: 1669 (88.1%), African‐American: 111 (5.9%), other: 115 (6.1%)
Residual disease details Reported categories for residual disease were as follows:

  1. NMRD: 437 (23.1%)

  2. SVRD (0.1 cm to 1 cm): 791 (41.7%)

  3. LVRD (> 1 cm): 667 (35.2%)


Optimal was not defined, yet women were divided into 3 groups for analysis, based on RD status (as above). The following chemotherapy schedules were given in the 6 trials:

  • GOG 111: IV paclitaxel 135 mg/m2, cisplatin 75 mg/m2, 6 cycles

  • GOG 114: IV paclitaxel 135 mg/m2, cisplatin 75 mg/m2, 6 cycles

  • GOG 132: IV paclitaxel 135 mg/m2, cisplatin 75 mg/m2, 6 cycles

  • GOG 152: IV paclitaxel 135 mg/m2, cisplatin 75 mg/m2, 6 cycles ± interval debulking

  • GOG 158: IV paclitaxel 135 mg/m2 (24 hours), cisplatin 75 mg/m2, 6 cycles or IV paclitaxel 175 mg/m2 (3 hours), carboplatin AUC 7.5, 6 cycles

  • GOG 172: IV paclitaxel 135 mg/m2, cisplatin 75 mg/m2, 6 cycles
Outcomes Overall survival and progression‐free survival: HR adjusted for age (discrete), race, GOG performance status, histology and tumour grade using Cox model:
SVRD vs NMRD: HR 2.11 (95% CI 1.78 to 2.49), P < 0.001 and HR 1.96 (95% CI 1.70 to 2.26), P < 0.001 for OS and PFS respectively
LVRD (> 1 cm) vs NMRD: HR 2.47 (95% CI 2.09 to 2.92), P < 0.001 and HR 2.36 (95% CI 2.04 to 2.73), P < 0.001 for OS and PFS respectively
Risk of bias (QUIPS) 1. Study participation (a‐f): low risk
Adequate number of participants and description of target population. Baseline characteristics, eligibility criteria, sampling frame and period/place study took place presented clearly.
2. Study attrition (a‐e): unclear risk
Unclear if patients with incomplete follow‐up were excluded before arriving at the stated sample size. Insufficient information to permit judgement.
3. Prognostic factor measurement (a‐f): low risk
Valid and reliable measurement of RD
Outcome level assessment:
Outcome: overall survival
4. Outcome measurement (a‐c): low risk
Valid and reliable measurement of outcome
5. Adjustment for other prognostic factors (a‐g): unclear risk
Age arbitrarily categorised. Model predicting OS adjusted for age, race, GOG performance status, histology, and tumour grade
6. Statistical analysis and reporting (a‐d): unclear risk
In methods, authors reported that all variables considered as potential prognostic factors were included in multivariate analyses, suggesting some conceptual framework
Outcome: progression‐free survival
4. Outcome measurement (a‐c): low risk
Valid and reliable measurement of outcome
5. Adjustment for other prognostic factors (a‐g): unclear risk
Age arbitrarily categorised. Model predicting PFS adjusted for age, race, GOG performance status, histology, and tumour grade.
6. Statistical analysis and reporting (a‐d): unclear risk
In methods, authors reported that all variables considered as potential prognostic factors were included in multivariate analyses, suggesting some conceptual framework.
Notes 1505 recurrences and 1323 deaths were identified during a median follow‐up period of 43 months:
The median PFS was 17.1 months (95% CI 16.4 to 17.8 months)
The median OS was 45.3 months (95% CI 43.0 to 47.7 months)
PFS for disease residual: 
NMRD: N = 437, PFS was 33.0 months, 0.1 cm to 1.0 cm: N = 791, PFS) was 16.8 months, LVRD (> 1 cm): N = 667, PFS was 14.1 months, P < 0.001
OS for disease residual: 
NMRD: N = 437, OS was 71.9 months, SVRD: N = 791, OS was 42.4 months, LVRD (> 1.0 cm): N = 667, OS was 35.0 months, P < 0.001
Increasing age was associated with decreased PFS and OS. Median PFS and OS were shorter for women with a performance status (PS) of 1 or 2 when compared with those with a PS of 0. No difference in median PFS was evident between PS 1 and PS 2 women, whereas the difference in median OS between the same groups was observed. Based on tumour histology, women with endometrioid histology had improved clinical outcomes compared with those with serous tumours. Women with mucinous or clear‐cell tumours had decreased PFS and OS. Women with mucinous cell type had a median OS of only 15 months compared with 24, 45 and 56 months for clear‐cell, serous and endometrioid cell types, respectively.
Women with NMRD had the longest PFS and OS 33 and 72 months, respectively compared with women with any gross residual disease. The differences in median PFS and OS between the SVRD and LVRD (> 1 cm) groups were also evident, albeit small (3 months in median PFS and 7 months in median OS). Women with grade 2 or 3 tumours were associated with decreased PFS and OS. Race was not significantly associated with PFS or OS.